The objective of Company has to date been to provide shareholders with an attractive income and capital return by investing its funds in a portfolio of unquoted and quoted UK MedTech companies which meet the relevant criteria under the VCT Rules. The Company targets well managed businesses with strong leadership, that can demonstrate established and proven concepts, and are seeking an injection of growth capital to support their continued development.
The company is managed by the Board of Directors. A performance fee of 10% is payable if dividends and capital distributions exceed the sum of 80GBX per share, which is the gross subscription of 100GBX less 20GBX income tax deemed by the Board.
The Directors expect to pay a final dividend each year. In the short term, dividend payments are restricted by the limited income generated by the investment portfolio of Company. It is expected, in due course, the Company will realise capital growth on the disposal of successful investments and distribute these to shareholders.